Breast cancer is not a disease confined to the breast organ alone. The current unified understanding of the academic community worldwide is that breast cancer is a systemic disease that requires standardized and comprehensive treatment measures. The main measures of current treatment include surgery, chemotherapy, radiotherapy, endocrine therapy, and molecular targeted therapy. For patients with different conditions, individualized treatment plans should be formulated according to their own characteristics and these treatment measures should be chosen reasonably. Among them, surgery and radiotherapy belong to the category of local treatment; other treatments belong to systemic treatment. Surgery is one of the main treatment methods for breast cancer, which is mainly to remove the tumor and breast gland, remove the lymphatic tissue and fatty tissue in the relevant area, and try to achieve the purpose of curing the tumor. However, surgery is not the only treatment, and it cannot replace other systemic treatments. Less than 5% of breast cancer types do not require follow-up treatment after surgery. The vast majority of breast cancers have a pathological type that determines that chemotherapy, endocrine therapy and other systemic treatments are also essential. The timing of surgery is also determined by the disease. Not all patients will undergo surgery first, and creating better conditions for surgery through systemic therapy will have a better prognosis for some patients. Chemotherapy is a chemotherapy regimen that is tailored to each patient’s condition and usually requires 6-8 cycles of chemotherapy, every 21 days or 14 days. There are several common side effects of chemotherapy drugs for breast cancer: nausea, vomiting, fatigue, leukopenia, hair loss, etc. Adjuvant treatment measures to alleviate side effects, enhance resistance and protect organ function will be targeted during the patient’s chemotherapy treatment. Radiotherapy, i.e. radiation therapy, is a local treatment measure that uses radiation to kill tumor cells and reduce the risk of recurrence, and is suitable for use under the conditions of post-breast-conserving surgery, axillary lymph node metastasis, local recurrence, bone metastasis, etc. In the comprehensive treatment of breast cancer in our hospital, after clarifying the patient’s initial local radiotherapy guideline, the physicians of breast specialist will invite radiotherapy physicians to consult with them to determine whether the patient is suitable for radiotherapy, whether there are contraindications to radiotherapy and to make radiotherapy plan. Endocrine therapy and molecular targeted therapy are not available for all patients and are determined by the immunohistochemical test results of the patient’s tumor, which are determined by the characteristics of the cancer cells themselves. In general, the so-called “triple negative breast cancer” with negative ER/PR/HER2 indicators are not suitable for endocrine therapy and molecular targeted therapy. targeted therapy. The choice of specific drugs depends on the patient’s condition, age, general status, etc.